Bicara Therapeutics (BCAX) Other Operating Expenses (2023 - 2026)

Bicara Therapeutics' Other Operating Expenses history runs 4 years deep, the most recent figure standing at $47.4 million for Q1 2026.

• On a quarterly basis, Other Operating Expenses rose 70.76% year-over-year to $47.4 million in Q1 2026; TTM through Mar 2026 was $172.5 million, a 107.46% increase from a year earlier, with the FY2025 full-year figure at $125.1 million, up 125.79% from the prior year.
• Other Operating Expenses declined to $47.4 million in Q1 2026 per BCAX's latest filing, from $125.1 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $125.1 million in Q4 2025 and bottomed at -$36000.0 in Q3 2024.
• The 4-year median for Other Operating Expenses is $41000.0 (2024), against an average of $23.2 million.
• Biggest YoY gain for Other Operating Expenses was 89201.61% in 2024; the steepest drop was 192.31% in 2024.
• Year by year, Other Operating Expenses stood at $62000.0 in 2023, then soared by 89201.61% to $55.4 million in 2024, then surged by 125.93% to $125.1 million in 2025, then sank by 62.11% to $47.4 million in 2026.
• Per Business Quant, the three latest BCAX Other Operating Expenses figures stand at $47.4 million (Q1 2026), $125.1 million (Q4 2025), and -$25000.0 (Q3 2025).